Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 44

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 44
---
 |     676,790 |     | 0.0%         |
| Vit Vasista(4)       |     |     500,018 |     |     500,018 |     | 0.0%         |

(1) Curran Simpson served as EVP, Chief Operating Officer through July 1, 2024, on which date he was appointed President and CEO. Mr. Simpson's annual base salary reported for 2023 relates to his compensation as EVP, Chief Operating Officer. Mr. Simpson's annual base salary was increased to $533,445 effective January 1, 2024 reflecting an increase of 4% compared to his 2023 base salary. Mr. Simpson's annual base salary was then further increased to $610,000 upon his appointment as President and CEO effective July 1, 2024. (2) Mitchell Chan joined the Company as EVP, Chief Financial Officer on September 16, 2024. (3) Kenneth T. Mills' last day of employment as President and CEO was July 1, 2024. (4) Vit Vasista's last day of employment as EVP and Chief Financial Officer was September 16, 2024. Annual Short-Term Cash Incentive We have an annual cash incentive program for all employees, which is intended to align corporate, departmental, and individual goals throughout the Company and to provide an incentive that further ties compensation to achievement of those goals. In establishing targets for the cash incentive awards for our NEOs, the Compensation Committee (and the Board, in the case of our President and CEO) considers cash incentive awards paid to executives in similar positions at our peer group companies. Target cash incentive award percentages for our NEOs in 2024, as compared to 2023, are reflected in the table below:

| Name                 |     | Target Cash        
 Incentive Award    
 for 2024           
 (% of Base Salary) |     | Target Cash        
 Incentive Award    
 for 2023           
 (% of Base Salary) |
| Curran Simpson(1)    |     | 60%                |     | 40%                |
| Mitchell Chan(2)     |     | 40%                |     | N/A                |
| Stephen Pakola, M.D. |     | 40%                |     | 40%                |
| Olivier Danos, Ph.D. |     | 40%                |     | 40%                |
| Patrick J